A Randomized Phase Ii Study Comparing Imatinib And The Combination Of Imatinib And Pegylated Interferon Alpha-2b In Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (Cml) Patients In Complete Hematological Remission After Imatinib Induction Therapy.